Bill would ease FDA testing rules for cheaper biosimilar drugs

What does this do?

The bill would end the automatic requirement for immunogenicity, pharmacodynamics, and comparative efficacy studies for biosimilar drug approval. Companies would instead only need to show safety and expected results in one approved use through simpler pharmacokinetic testing. The FDA could still require the extra studies case by case, but only with early written notice explaining why.

Who does it affect?

This mainly affects pharmaceutical companies developing biosimilar drugs, which are cheaper alternatives to complex biologic medicines used for conditions like arthritis, cancer, or diabetes. Patients and doctors could also be affected through changes in access to and confidence in these drugs.

Why does it matter?

Fewer required studies could shorten approval timelines and lower development costs for biosimilar makers, while raising questions for some about whether reduced testing affects confidence in drug safety or effectiveness. The change would apply only to applications submitted after the law takes effect.

Where does it stand?